Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intensive vs Standard Adjuvant Chemotherapy in Localized Colon Cancer With Circulating Tumor DNA
NCT07821333Phase 2Active, not recruiting
- Sponsor
- INCLIVA Biomedical Research Institute
- Start
- Jan 2022
- Primary completion
- Jan 2027
- Countries
- 1
01
Overview
A Phase 2 trial of FOLFIRINOX in colon cancer, sponsored by INCLIVA Biomedical Research Institute. Started Jan 2022; status: active, not recruiting.
02
Drugs
FOLFIRINOX
03
Conditions
colon cancer
Beyond the preview
Go deeper on NCT07821333.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07821333.